Although substantial progress has been made towards improving gender- and sex-specific ACS disease management and outcomes, contemporary reports indicate a persistent knowledge gap with regard to optimal risk-stratification and management in female ACS patients. Prominent patient and system delays in women with AMI result from limited awareness for the latent CVD risk in women, a lack of sexspecific thresholds within clinical guidelines, and subsequent limited performance of contemporary diagnostic approaches in women, all of which are the result of a persistent underrepresentation of women in cardiovascular studies